CAC
ACET icon

Cowen and Company’s Adicet Bio ACET Stock Holding History

Cowen and Company’s Portfolio ACET Stock Details ACET Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q3 		– Sell
-50,081
Closed -$970K – 618
2024
Q2 		$970K Sell
50,081
-3,678
-7% -$98.6K 0.03% 149
2024
Q1 		$2.02M Sell
53,759
-115,946
-68% -$4.8M 0.08% 121
2023
Q4 		$5.13M Hold
169,705
– – 0.34% 50
2023
Q3 		$3.72M Sell
169,705
-7,474
-4% -$264K 0.26% 70
2023
Q2 		$6.89M Sell
177,179
-19,297
-10% -$1.7M 0.57% 42
2023
Q1 		$18.1M Hold
196,476
– – 2.13% 13
2022
Q4 		$28.1M Buy
196,476
+43,773
+29% +$10.9M 2.94% 9
2022
Q3 		$34.7M Sell
152,703
-33
-0% -$8.38K 3.32% 7
2022
Q2 		$35.7M Buy
152,736
+58,983
+63% +$13M 3.45% 5
2022
Q1 		$30M Buy
+93,753
New +$21.6M 2.88% 8

Other funds holding ACET

O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
TCM
Tang Capital Management San Diego, California $1.97B AUM 125.1% 1-Year Est. Return
RCM
RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
CG
Carlyle Group Washington, District of Columbia $10.6B AUM 11.25% 1-Year Est. Return
ACM
Aquilo Capital Management San Francisco, California $55.8M AUM 41.76% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Acadian Asset Management
Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return
Blackstone Inc
Blackstone Inc New York $25.6B AUM 26.83% 1-Year Est. Return

Cowen and Company's ACET Position: Q3 2024 in Review

Cowen and Company sold out of Adicet Bio (ACET) in Q3 2024, closing a stake of 50,081 shares — an estimated $970K sold.

Cowen and Company first reported a position in ACET in Q1 2022 and held it in 10 quarters. The position peaked at $35.7M in Q2 2022. 64 funds tracked by Wall St. Rank hold ACET as of Q3 2024.

  • Cowen and Company reported no remaining Adicet Bio position as of Q3 2024 after selling out during the quarter.
  • Cowen and Company sold 50,081 Adicet Bio shares in Q3 2024, an estimated $970K.
  • Cowen and Company first reported a position in Adicet Bio in Q1 2022 and held it in 10 quarters.
  • Cowen and Company's Adicet Bio position peaked at $35.7M in Q2 2022.
  • 64 funds tracked by Wall St. Rank held Adicet Bio as of Q3 2024.

Based on Cowen and Company's 13F filing for Q3 2024, filed 12 Nov 2024.